AB1314 SAFETY AND EFFICACY OF LONG-TERM TOCILIZUMAB IN A COHORT OF PATIENTS WITH GIANT CELL ARTERITI...
AB1314 SAFETY AND EFFICACY OF LONG-TERM TOCILIZUMAB IN A COHORT OF PATIENTS WITH GIANT CELL ARTERITIS: AN ITALIAN MONOCENTRIC RETROSPECTIVE STUDY
About this item
Full title
Author / Creator
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Background:Tocilizumab (TCZ) is the only biologic drug approved for the treatment of giant cell arteritis (GCA), having clinical trials and real-life studies proved its efficacy and safety. However, optimal duration of the treatment has yet to be determined, being its early interruption associated with an increased risk of relapse. Conversely, prol...
Alternative Titles
Full title
AB1314 SAFETY AND EFFICACY OF LONG-TERM TOCILIZUMAB IN A COHORT OF PATIENTS WITH GIANT CELL ARTERITIS: AN ITALIAN MONOCENTRIC RETROSPECTIVE STUDY
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3100834150
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3100834150
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2024-eular.794
